BridgeMD
Platelet function testing in outpatients after heart transplantation on aspirin therapy
EU CTIS ID: 2025-521699-71-01
What this study is testing
To assess the prevalence of aspirin resistance in patients 12 to 18 months after heart transplantation.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients between 18 and 99 years of age
- Patients who are on aspirin therapy
- Patients who had their heart transplantation 12 to 18 months prior to the date of study inclusion
You likely can't join if
- Patients with a platelet count lower than 100,000 /µL
- Patients who are pregnant
- Patients who are breast feeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.